Showing 1431-1440 of 3103 results for "".
- Study Shows Mobile Stroke Units Lead to Better Outcomeshttps://practicalneurology.com/news/study-shows-mobile-stroke-units-lead-to-better-outcomes/2469684/A study published in The New England Journal of Medicine found that people with acute ischemic stroke had better outcomes when treated in a mobile stroke unit (MSU) instead of a standard emergency medical services (EM
- Mixed Sodium Oxybates Improve Idiopathic Hypersomniahttps://practicalneurology.com/news/mixed-sodium-oxybates-improve-idiopathic-hypersomnia/2469574/In a phase 3 study (NCT03533114) of mixed salt oxybates (MSO) (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) for treatment of idiopathic hypersomnia (IH) showed improvement on multiple measures. All participants first received tr
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
- Outcomes of Ischemic Stroke Care in Mobile Stroke Units Superior to Ambulanceshttps://practicalneurology.com/news/outcomes-of-ischemic-stroke-care-in-mobile-stroke-units-superior-to-ambulances/2469533/Data from the BEST-MSU study (NCT02190500) presented at the International Stroke Conference, held online March 17-19, 2021, showed care for individuals with ischemic stroke in mobile stroke units (MSUs) was superior compared with stand
- Nanocatalytic Gold Treatment Improves Multiple Sclerosis Functional Composite Scores in Phase 2 Studieshttps://practicalneurology.com/news/nanocatalytic-gold-treatment-improves-multiple-sclerosis-functional-composite-scoresin-phase-2-studies/2469513/Treatment with the bioenergetic catalyst nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) improved Multiple Sclerosis Functional Composite (MSFC) scores significantly more than placebo. Participants in the trial continued taking disease-modifying treatments approved for the
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
- Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Ratehttps://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi
- Study Examining Ocrelizumab Treatment in African-Americans, Hispanic- and Latinx-Americans Is Actively Enrollinghttps://practicalneurology.com/news/study-examining-ocrelizumab-treatment-in-african-americans-hispanic-and-latinx-americans-is-actively-enrolling/2469376/A new study to characterize the response to ocrelizumab (Ocrevus; Genentech, South San Francisco, CHIMES (NCT04377555) in individuals from traditionally underrepresented groups was announced at MSVirtual2020 conference. This is the fir
- Phase 2 Clinical Trial for Stem-Cell Treatment of Alzheimer Disease Plannedhttps://practicalneurology.com/news/phase-2-clinical-trial-for-stem-cell-treatment-of-alzheimer-disease-planned/2469305/A phase 2 clinical trial to evaluate the safety and efficacy of treatment in individuals with prodromal to mild Alzheimer disease (AD) is planned for the autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY). The program is be
- Verdiperstat, a Potential Treatment for Multiple System Atrophy, Granted Orphan Drug Statushttps://practicalneurology.com/news/verdiperstat-a-potential-treatment-for-multiple-system-atrophy-granted-orphan-drug-status/2468829/The Food and Drug Administration has granted orphan drug status to verdiperstat (BHV-3241; Biohaven Pharmaceutical, New Haven, CT). Verdiperstat is a novel brain-penetrant myeloperoxidase (MPO) inhibitor being studied as a potential first-in-class treatment for multiple system atrophy (MSA). Verd